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Background: We investigated the association between oxcarbazepine (OXC)-induced maculopapular eruption
(MPE) and HLA-B alleles in a northern Han Chinese population, and conducted an analysis of clinical risk factors for
OXC-MPE.
Methods: Forty-two northern Han Chinese patients who had been treated with OXC in Changchun, China were
genotyped. Among them were 14 cases with OXC-induced MPE; the remaining 28 were OXC-tolerant. The HLA-B
allele frequencies of the normal control group were found in the Allele Frequency Net Database. Polymerase chain
reaction-sequence specific primer( PCR-SSP )was used for HLA-B*1502 testing and direct sequencing for four-digit
genotype determination.
Results: Four-digit allele sequencing showed that there was no statistically significant difference in the frequency
of the HLA-B*1502 allele between the OXC-MPE and OXC-tolerant controls (3.6% versus 7.5%, OR = 0.38, 95%
CI = 0.04–3.40, P = 0.65), as well as between OXC-MPE and normal controls (3.6% versus 2.4%, OR = 1.54, 95%
CI = 0.20–11.73, P = 0.49). However, a significant difference in the frequency of HLA-B*3802 alleles was found
between the MPE group and normal controls (10.7% versus 1.9%, OR = 6.329, 95% CI = 1.783-22.460, P = 0.018).
There was no significant difference in terms of age, gender, or final OXC dose between the OXC-MPE and
OXC-tolerant groups.
Conclusions: There was no significant association between OXC-MPE and HLA-B*1502 in the northern Han Chinese
population in our study. Instead, HLA-B*3802 was found to be a potential risk factor for OXC-MPE.
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The new antiepileptic drug (AED) oxcarbazepine (OXC) is
a 10-keto analog of carbamazepine (CBZ). The clinical
effectiveness of OXC is similar to that of CBZ, but with
fewer adverse drug reactions (ADRs), which is attributed
to their different metabolic pathways [1]. A common side
effect associated with AED use is rash, and has been the
leading cause of withdrawal from some AED trials [2-4].
Recently it was reported that the incidence of OXC-
related skin rashes is 3-8% in Norwegian [5,6] patients.* Correspondence: madihui@263.net; stoneyiwu@sohu.com
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reproduction in any medium, provided the orCutaneous adverse drug reactions (cADRs) induced by
AEDs range from mild maculopapular eruption (MPE)
and hypersensitivity syndrome, to the more severe
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN). Among these cADRs, MPE is the most
common [7], and is generally considered an initial form
of the other, more severe, cADRs.
The pathogenesis of AED-induced cADRs is complex—
several studies have indicated that T-cell-mediated allergic
reactions might be associated with them [8], but genetic
susceptibility and the exact pathogenesis are not fully
understood and require further investigation. Recent
studies have reported that the HLA-B*1502 allele is
strongly associated with a dramatically increased risk of
CBZ-induced SJS/TEN, but not MPE, among HanThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in southern China.
Owing to the structural similarity between OXC and
CBZ, several studies of genetic susceptibility to OXC have
been performed and an association between HLA-B*1502
and OXC-cADRs has been reported. These included studies
that suggested that HLA-B*1502 may be associated with
OXC-induced SJS/TEN [11,12]. Other studies such as Zhou
D [13]reported that the HLA-B*1502 allele may contribute
to genetic susceptibility to OXC-induced MPE in the
Chinese Han population. However, there are also studies
which found no significant association between HLA-B*
1502 and OXC-MPE in southern Han Chinese people
[14]. Because of the inconsistencies among these results
and the fact that there has been no study conducted to
test the association between HLA-B*1502 and OXC-MPE
in the northern Han Chinese population specifically, we
carried out the following retrospective study. Herein we
report our investigations into the association between
OXC-induced MPE and HLA-B alleles. We also analyzed
the clinical risk factors for OXC-induced MPE in a northern
Han Chinese population.Methods
Patients
All of the enrolled subjects (patients and normal controls)
were of Northern Han Chinese ethnicity. Patients were
from towns in Jilin Province (Hua Dian, Pan Shi, Tao Nan,
Jiao He, and Shu Lan). The Ethics Committee of Jilin
University at Changchun, and the Ethics Committee
of Second Affiliated Hospital of Guangzhou Medical
University at Guangzhou approved this study. All of the
study participants provided written informed consent.
During the years 2010–2012, 14 cases that fulfilled the
diagnostic criteria for OXC-induced MPE (OXC-MPE)
were identified at the Department of Neurology, First
Hospital of Jilin University, Changchun, China. MPE was
defined as erythematous exanthema without blistering or
postulation. The attribution of MPE to OXC treatment
was determined jointly by the treating epileptologist and
dermatologist.
We enrolled 28 subjects who had been administered
OXC for more than 3 months but had not developed
any cADRs (OXC-tolerant). In addition, for the normal
control group we used the HLA-B allele frequencies
reported in the Allele Frequency Net Database. Two
control groups were used in this study, including
618 persons in Beijing, Shijiazhuang, Tianjin and 105
persons in the northern Han population (http://www.
allelefrequencies.net).
Data collected from the patients’ records included:
age, gender, initial and final dose of OXC, and latency to
MPE (starting from the initial dose).Method
DNA was extracted from peripheral blood using a
QIARamp blood mini kit (Qiagen, Hilden, Germany). The
presence of HLA-B*1502 was examined via polymerase
chain reaction with sequence-specific primers as in previ-
ous reports [14,15]. Sequencing for four-digit genotype
determination was performed for all of the OXC-MPE and
OXC-tolerant patients on an ABI 3730 sequencer (Applied
Biosystems, Foster City, CA, USA). The forward and reverse
primer sequences were Bin1-TAF (5'-TGGCGGGGGC
GCAGGACCTGA-3') or Bin1-CGF (5'-TCGGGGGCGC
AGGACCCGG-3') and Bin3-R (5'-CGGAGGCCATCCCC
GGCGACCTAT-3'). Four-digit alleles of HLA-B in all
patients were determined by sequence alignment using the
immunogenetics/human leukocyte antigen (IMGT/HLA)
database (http://www.ebi.ac.uk/imgt/hla) and the software
vector NTI 6.0 (InforMax, Gaithersburg, MD, USA).
Statistical analysis
Student’s t-test for independent samples was used to
determine the significance of differences in mean age
and dosage between the OXC-MPE and the OXC-tolerant
groups. The chi-squared test and Fisher’s exact test were
carried out to analyze the association between OXC-MPE
and HLA-B alleles. To reduce bias in estimating the odds
ratio (OR), whenever a zero-count field was encountered,
0.5 was added to all the fields in the 2×2 table [16]. The
P-value from continuity correction (n ≥ 40 but 1 ≤ T ≤5)
or Fisher’s exact test (n < 40 or T < 1), as well as estimated
ORs and 95% exact confidence intervals (CIs), were
established. P-values less than 0.05 (two-sided) were
considered statistically significant. All analyses were
performed using SPSS version 16.0 software (SPSS,
Chicago, IL, USA).
Results
Fourteen patients who had been diagnosed with OXC-
induced MPE (9 females, 5 males; mean age 34.43 ±
12.10 y) and 28 patients who received OXC for at least 3
months without any evidence of adverse drug reactions
(17 females, 11 males; mean age 34.04 ± 12.85 y) were
enrolled as cases (OXC-MPE) and tolerant controls
(OXC-tolerant), respectively. For the normal control
group, we used the Allele Frequency Net Database
(http://www.allelefrequencies.net, see Table 1).
The genotyping showed that HLA-B*1502 was present
in only one of the 14 (7.1%) OXC-MPE patients, whereas
5 of the 28 (17.9%) OXC-tolerant controls carried this
allele. The differences in the presence of HLA-B*1502
between the two groups was not statistically significant
(OR = 0.35, 95% CI = 0.04–3.36, P = 0.64).
Four-digit allele sequencing showed that there was no
statistically significant difference in the frequency of the
HLA-B*1502 allele between the OXC-MPE and the OXC-
Table 1 Clinical characteristics and genotypes in the 14 patients with OXC-induced MPE and in the 28 OXC-tolerant
controls
OXC-induced MPE
ID No. Gender Phenotype Initial-dose (mg) Final-dose (mg) Latency (d) Concurrent drug HLA-B 1502 Four-digit allele
1 M MPE 300 600 12 N Negative HLA-B*4001/4001
2 F MPE 300 600 11 N Negative HLA-B*1302/4601
3 F MPE 300 450 16 N Negative HLA-B*1302/1302
4 M MPE 300 600 9 N Negative HLA-B*1501/5101
5 F MPE 300 450 15 N Negative HLA-B*1501/1527
6 M MPE 300 600 12 N Negative HLA-B*1501/4403
7 F MPE 300 900 16 N Negative HLA-B*1501/1542
8 M MPE 300 600 11 N Negative HLA-B*4001/1558
9 F MPE 300 900 17 N Negative HLA-B*3802/4403
10 F MPE 300 450 8 N Negative HLA-B*5201/5301
11 F MPE 300 600 10 N Negative HLA-B*5502/5601
12 F MPE 300 750 14 N positive HLA-B*3802/1502
13 M MPE 300 750 12 N Negative HLA-B*1301/1301
14 F MPE 300 600 9 N Negative HLA-B*4402/3802
OXC-tolerant
ID No. Gender Phenotype Initial-dose (mg) Final-dose (mg) Latency (d) Concurrent drug HLA-B 1502 Four-digit allele
15 F Tolerant 300 900 N N Negative HLA-B*4801/3531
16 F Tolerant 300 600 N N Negative HLA-B*4403/4804
17 M Tolerant 300 600 N N Negative HLA-B*4001/5501
18 M Tolerant 300 900 N N Negative HLA-B*3802/4403
19 F Tolerant 300 900 N N Negative HLA-B*4403/4403
20 M Tolerant 300 600 N N Negative HLA-B*3802/1302
21 F Tolerant 300 600 N N Negative HLA-B*4801/3531
22 M Tolerant 300 450 N N Negative HLA-B*4601/1511
23 M Tolerant 300 600 N N Negative HLA-B*1501/4001
24 F Tolerant 300 450 N N Negative HLA-B*1511/4801
25 F Tolerant 300 600 N N Negative HLA-B*4403/5604
26 F Tolerant 300 900 N N Negative HLA-B*1302/5801
27 M Tolerant 300 900 N N Negative HLA-B*1302/0705
28 F Tolerant 300 600 N N Negative HLA-B*3710/4701
29 F Tolerant 300 600 N N Negative HLA-B*1302/1315
30 F Tolerant 300 600 N N Negative HLA-B*1302/3901
31 F Tolerant 300 900 N N Negative HLA-B*5102/3508
32 M Tolerant 300 900 N N Negative HLA-B*5502/3801
33 F Tolerant 300 450 N N Negative HLA-B*1501/1513
34 F Tolerant 300 600 N N Negative HLA-B*1301/1301
35 M Tolerant 300 600 N N Negative HLA-B*2705/5101
36 M Tolerant 300 450 N N Negative HLA-B*4801/4801
37 F Tolerant 300 600 N N positive HLA-B*1502/4001
38 F Tolerant 300 750 N N positive HLA-B*5801/1502
39 F Tolerant 300 900 N N Negative HLA-B*4001/4006
40 M Tolerant 300 600 N N positive HLA-B*1502/5801
41 M Tolerant 300 450 N N positive HLA-B*4601/1502
42 F Tolerant 300 900 N N positive HLA-B*4601/1502
OXC, oxcarbazepine; MPE, maculopapular eruption; F, female; M, male.
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CI = 0.04–3.40, P = 0.65), as well as between the OXC-
MPE group and the normal control group (3.6% versus
2.4%, OR = 1.54, 95% CI = 0.20–11.73, P = 0.49). More-
over, there were no significant differences between the
OXC-MPE and the OXC-tolerant groups with regard to
the frequencies of other HLA-B alleles. However, when
the general northern Han population was used as a
normal control, the frequency of the HLA-B*3802 allele
was found to be significantly higher in the OXC-MPE
group (10.7% versus 1.9%, OR = 6.329, 95% CI = 1.783-
22.460, P = 0.018; Table 2).
There was no significant difference between the patients
with or without OXC-MEP in terms of age (34.43 ± 12.10
versus 34.04 ± 12.85, P = 0.93), gender (male/female: 5/9
versus 11/17, OR = 0.86, 95% CI = 0.23-3.25, P = 0.82), or
final dose (632.14 ± 146.24 mg/d versus 675.00 ± 170.78
mg/d, P = 0.43; Table 1).
Discussion
In the present study we found no association between
OXC-induced MPE and HLA-B*1502 in our northern
Han Chinese patients. Our result is consistent with
previous studies of southern Han Chinese [14], but
different from another study showing a significant as-
sociation between OXC-induced MPE and HLA-B*1502
in central Han Chinese [7]. These discrepancies could
mainly be due to differences in the frequency of HLA-B
*1502 in different populations. Of note, in each of these
studies the sample size was small, which limited the power
of the statistical analyses.
Among Han Chinese living in Taiwan and Hong Kong
(southern China), HLA-B*1502 was strongly associated
with a dramatically increased risk of CBZ-induced SJS/
TEN, but was not associated with MPE [10]. Recently,
three OXC-induced SJS/TEN cases reported from Taiwan
were positive for HLA-B*1502 [17], and there was one
case of OXC-induced SJS positive for HLA-B*1502 in
India [18]. This suggests a very strong association between
OXC-induced SJS/TEN and the HLA-B*1502 allele. In
our study, we found that the HLA-B*1502 allele was only
present in 7.1% of OXC-induced MPE patients in this
northern Han Chinese population.
This may be due to the inflammatory immune reactions
of MPE different from SJS/TEN. CD4 + T cells are the
major cell type found in the skin lesions of MPE [19],
whereas CD8 + T-cell-mediated cytotoxic responses
appear to be the major event in SJS/TEN [20].
OXC is a new AED which has shown clinical effective-
ness similar to that of CBZ but with fewer adverse drug
reactions; therefore OXC is now frequently used as a
substitute for CBZ. Rash is a common side effect of
AED therapy and is the leading cause of withdrawal
from AED prescriptions. Some of these rashes can beameliorated by early-stage therapy with additional
management to prevent them from developing into
more severe cutaneous reactions that could be fatal,
while discontinuing OXC due to skin eruption prevents
the long-term use of what would otherwise be an effective
drug, and increases the suffering of patients. Hence, iden-
tifying the possible risk factors for cADRs will contribute
to their prevention and the safe use of OXC.
We therefore compared the frequencies of HLA-B
alleles other than HLA-B*1502 between the OXC-MPE
and the OXC-tolerant groups. We found an association
between the HLA-B*3802 allele and OXC-induced MPE
in the northern Han Chinese population we studied; the
frequency of the HLA-B*3802 allele was significantly
higher in the OXC-MPE group. However, it should be
noted that the general northern Han population was used
as a control group. When OXC-tolerant subjects were used
as a control, there was no statistically significant difference
in the frequency of the HLA-B*3802 allele between the
OXC-MPE and the OXC-tolerant control groups. This
discrepancy may be because this is a small sample study,
and therefore the statistical power to detect any significant
difference between cases and controls was limited. Whether
the HLA alleles identified in this exploratory study would
be associated with the development of OXC-induced MPE
in a larger sample needs to be investigated.
Hung et al. [9] found that MPE induced by CBZ was
associated with single nucleotide polymorphisms (SNPs)
in the HLA-E region and the nearby allele HLA-A*3101,
but hypersensitivity syndrome was associated with SNPs
in the motilin gene located terminal to the major histo-
compatibility complex (MHC) class II genes [8]. Therefore,
the association between OXC-induced skin rashes and
other HLA alleles beyond HLA-B should be explored in
future research.
Our analysis of potential risk factors for OXC-induced
MPE in the present study showed that neither age, gender,
nor final dose of OXC were associated with incidence of
the skin rash, which is consistent with previous studies in
Korea [21]. However, other related studies showed that
several clinical variables affected skin reactions, including
gender, hormones, the drug titration schedule, and co-
medication [22]. Among these variables, a high starting
dose and rapid dose escalation were identified as risk fac-
tors, especially for the AED lamotrigine, and particularly
when administered concurrent with valproate [23]. In
addition, it has been reported that a reaction to one AED
may induce hypersensitivity to a previously tolerated AED,
and a previous AED-related skin reaction appears to be a
considerable risk factor for occurrence of another rash
[24]. The differences between our study and those cited
above may be because all of the patients in our study were
given monotherapy, treated with the same initial dosage,
and the small sample size.
Table 2 Frequencies of HLA-B alleles and their associations with OXC-induced MPE
Frequency MPE cases compared
with OXC-tolerant controls
MPE cases compared with
normal population controls
Alleles MPE a OXC-tolerant controls b Population controls c,d OR (95% CI) P OR (95% CI) P
0705 0/28 (0) 1/56 (1.8) 4/1236 c (0.4) 0.65 (0.03–16.45) 1.00 4.81 (0.25–91.38) 1.00
1301 2/28 (7.1) 2/56 (3.6) 44/1236 c (3.6) 2.08 (0.28–15.58) 0.86 2.08 (0.48–9.06) 0.62
1302 3/28 (10.7) 5/56 (8.9) 69/1236 c (5.5) 1.22 (0.27–5.54) 1.00 2.03 (0.60–6.89) 0.46
1315 0/28 (0) 1/56 (1.8) – 0.65 (0.03–16.45) 1.00 – –
1501 4/28 (14.3) 2/56 (3.6) 86/1236 c (7.0) 4.50 (0.77–26.27) 0.18 2.23 (0.76–6.57) 0.26
1502 1/28 (3.6) 5/56 (8.9) 29/1236 c (2.4) 0.38 (0.04–3.40) 0.65 1.54 (0.20–11.73) 0.49
1511 0/28 (0) 2/56 (3.6) 21/1236 c ( 1.7) 0.38 (0.02–8.24) 0.55 0.99 (0.06–16.78) 1.00
1513 0/28 (0) 1/56 (1.8) 1/1236 c (0.1) 0.65 (0.03–16.45) 1.00 14.45 (0.58–362.44) 1.00
1527 1/28 (3.6) 0/56 (0) 2/1236 c (0.2) 6.16 (0.24–156.27) 0.33 22.85 (2.01–259.72) 0.07
1542 1/28 (3.6) 0/56 (0) 0/210 d (0) 6.16 (0.24–156.27) 0.33 22.96 (0.91–577.76) 0.12
1558 1/28 (3.6) 0/56 (0) 2/1236 c (0.2) 6.16 (0.24–156.27) 0.33 22.85 (2.01–259.72) 0.07
2705 0/28 (0) 1/56 (1.8) 6/1236 c (0.5) 0.65 (0.03–16.45) 1.00 3.32 (0.18–60.38) 1.00
3508 0/28 (0) 1/56 (1.8) 1/1236 c (0.1) 0.65 (0.03–16.45) 1.00 14.45 (0.58–362.44) 1.00
3531 0/28 (0) 2/56 (3.6) 0/210 d (0) 0.38 (0.02–8.24) 0.55 – –
3710 0/28 (0) 1/56 (1.8) – 0.65 (0.03–16.45) 1.00 – –
3801 0/28 (0) 1/56 (1.8) 8/1236 c (0.7) 0.65 (0.03–16.45) 1.00 2.54 (0.14–45.00) 1.00
3802 3/28 (10.7) 2/56 (3.6) 23/1236 c (1.9) 3.24 (0.51–20.63) 0.42 6.329 (1.783–22.460) 0.018 e
3901 0/28 (0) 1/56 (1.8) 23/1236 c (1.9) 0.65 (0.03–16.45) 1.00 0.91 (0.05–15.29) 1.00
4001 3/28 (10.7) 4/56 (7.1) 100/1236 c (8.1) 1.56 (0.32–7.51) 0.89 1.36 (0.41–4.59) 0.88
4006 0/28 (0) 1/56 (1.8) 39/1236 c (3.2) 0.65 (0.03–16.45) 1.00 0.53 (0.03–8.87) 1.00
4402 1/28 (3.6) 0/56 (0) 11/1236 c (0.9) 6.16 (0.24–156.27) 0.33 4.13 (0.51–33.09) 0.24
4403 2/28 (7.1) 5/56 (8.9) 32/1236 c (2.6) 0.79 (0.14–4.32) 1.00 2.89 (0.66–12.72) 0.17
4601 1/28 (3.6) 3/56 (5.4) 118/1236 c (9.6) 0.65 (0.07–6.59) 1.00 0.35 (0.05–2.61) 0.46
4701 0/28 (0) 1/56 (1.8) 0/210 d (0) 0.65 (0.03–16.45) 1.00 – –
4801 0/28 (0) 5/56 (8.9) 24/1236 c (2) 0.16 (0.01–3.08) 0.25 0.87 (0.05–14.63) 1.00
4804 0/28 (0) 1/56 (1.8) 0/210 d (0) 0.65 (0.03–16.45) 1.00 – –
5101 1/28 (3.6) 1/56 (1.8) 66/1236 c (5.4) 2.04 (0.12–33.83) 1.00 0.66 (0.09–4.91) 1.00
5102 0/28 (0) 1/56 (1.8) 6/1236 c (0.5) 0.65 (0.03–16.45) 1.00 3.32 (0.18–60.38) 1.00
5201 1/28 (3.6) 0/56 (0) 21/1236 c (1.9) 6.16 (0.24–156.27) 0.33 2.14 (0.28–16.51) 0.39
5301 1/28 (3.6) 0/56 (0) 0/210 d (0) 6.16 (0.24–156.27) 0.33 22.96 (0.91–577.76) 0.12
5501 0/28 (0) 1/56 (1.8) 7/1236 c (0.6) 0.65 (0.03–16.45) 1.00 2.88 (0.16–51.58) 1.00
5502 1/28 (3.6) 1/56 (1.8) 35/1236 c (2.9) 2.04 (0.12–33.83) 1.00 1.27 (0.17–9.62) 0.56
5601 1/28 (3.6) 0/56 (0) 2/1236 c (0.2) 6.16 (0.24–156.27) 0.33 22.85 (2.01–259.72) 0.07
5604 0/28 (0) 1/56 (2.5) 1/1236 c (0.1) 0.65 (0.03–16.45) 1.00 14.45 (0.58–362.44) 1.00
5801 0/28 (0) 3/56 (5.3) 74/1236 c (6) 0.27 (0.01–5.38) 0.55 0.27 (0.02–4.53 ) 0.35
a 2n = 28.
b 2n = 56.
c 2n = 1236, from a China Beijing Shijiazhuang Tianjin Han population of 618 persons (http://www.allelefrequencies.net).
d 2n = 210, from a China North Han population of 105 persons (http://www.allelefrequencies.net). Note: The frequency of these alleles has not been reported by
the former.
OXC, oxcarbazepine; MPE, maculopapular eruption; OR, odds ratio; CI: confidence interval.
e P < 0.05 (two-sided) was statistically significant.
–, no data available.
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In conclusion, we found no significant association
between OXC-induced MPE and the HLA-B*1502
allele in the northern Han Chinese patients we stud-
ied. Instead, in this Han Chinese population HLA-B*3802 was identified as a potential risk factor for
OXC-MPE. Furthermore, no association was found
between OXC-MPE and age, gender, or dosage. It
should be noted that this is a small-sample study,
which limited the statistical power to detect any
Lv et al. BMC Neurology 2013, 13:75 Page 6 of 6
http://www.biomedcentral.com/1471-2377/13/75significant difference. Therefore, our results need to
be further confirmed by a future study with a larger
sample size.
Abbreviations
AED: Antiepileptic drug; cADR: Cutaneous adverse drug reaction;
CBZ: Carbamazepine; CI: Confidence interval; MPE: Mild maculopapular
eruption; OR: Odds ratio; OXC: Oxcarbazepine; PCR: Polymerase chain
reaction; SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis.
Competing interests
The authors declared no potential conflicts of interest with respect to the
research, authorship, finance and/or publication of this article.
Authors' contributions
All authors have read and approved the final manuscript. YDL and FLM
contributed equally to this work, as First Authors. YDL contributed to the
conception, design, acquisition of data, and writing. FL M contributed to
analysis, interpretation of data, and writing. D-HM and YWS contributed
equally as corresponding author. DHM contributed to giving final approval
of the version to be published; Y-WS contributed to manuscript revision,
general supervision of the research group, and giving final approval of the
version to be published. WPL participated in the design of the study. NH
performed the statistical analysis and revising. TZ participated in the
sequence alignment.
Acknowledgements
This work was supported by Yangcheng scholar research project of
Guangzhou Municipal College (No.12A017G, Yi-Wu Shi).
Received: 8 January 2013 Accepted: 28 June 2013
Published: 8 July 2013
References
1. Rambeck B, Specht U, Wolf P: Pharmacokinetic interactions of the new
antiepileptic drugs. Clin Pharmacokinet 1996, 31:309–24.
2. Chadwick D, Shaw MBM, Foy P, Rawlins MD, Turnbull DM: Serum
anticonvulsant concentrations and the risk of drug induced skin
eruptions. J Neurol Neurosurg Psychiatry 1984, 47(6):642–4.
3. Kramlinger KG, Phillips KA, Post RM: Rash complicating carbamazepine
therapy. J ClinPsychopharmacol 1994, 14(6):408–13.
4. Brodie MJ, Richens A, Yuen AW: Double-blind comparison of lamotrigine
and carbamazepine in newly diagnosed epilepsy. Lancet 1995,
345(8948):476–9.
5. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR, Bazil CW: Cross-
sensitivity of skin rashes with antiepileptic drug use. Neurology 2008,
71(19):1527–34.
6. Alvestad S, Lydersen S, Brodtkorb E: Rash from antiepileptic drugs:
influence by gender, age, and learning disability. Epilepsia 2007,
48(7):1360–5.
7. Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D: Pilot association study of
oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B
*1502 allele in Chinese Han population. Seizure 2011, 20(2):160–2.
8. Zanni MP, Schnyder B, von Greyerz S, Pichler WJ: Involvement of T cells in
drug-induced allergies. Trends Pharmacol Sci 1998, 19(8):308–10.
9. Hung SI, Chung WH, Jee SH, et al: Genetic susceptibility to
carbamazepine-induced cutaneous adverse drug reactions.
Pharmacogenet Genom 2006, 16(4):297–306.
10. Man CB, Kwan P, Baum L, et al: Association between HLA-B*1502 allele
and antiepileptic drug-induced cutaneous reactions. Epilepsia 2007,
48(4):1015–8.
11. Shankarkumar U, Shah KN, Ghosh K: HLA B*1502 allele association with
oxcarbamazepine-induced skin reactions in epilepsy patient from India.
Epilepsia 2009, 50(7):1837–8.
12. Chen YC, Chu CY, Hsiao CH: Oxcarbazepine-induced Stevens-Johnson
syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol
Venereol 2009, 23(6):702–3.
13. Wu XT, Hu FY, An DM, Yan B, Jiang X, Zhou D, et al: Association between
carbamazepine-induced cutaneous adverse drug reactions and the
HLA-B*1502 allele among patients in central China. Epilepsy Behav 2010,
19(3):405–8.14. He N, Min FL, Shi YW, Guo J, Liu XR, Li BM, et al: Cutaneous reactions
induced by oxcarbazepine in Southern Han Chinese: Incidence, features,
risk factors and relation to HLA-B alleles. Seizure 2012, 21(8):614–8.
15. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al: Medical
genetics: a marker for Stevens Johnson syndrome. Nature 2004,
428(6982):486.
16. Svensson CK, Cowen EW, Gaspari AA: Cutaneous drug reactions. Pharmacol
Rev 2001, 53(3):357–79.
17. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, et al: Common risk
allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome
and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010,
11(3):349–56.
18. Sharma SR, Sharma N, Yeolekar ME: Oxcarbazepine-induced Stevens-
Johnson syndrome: a case report. Indian Dermatol Online J 2011,
2(1):13–15.
19. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, et al:
Hypersensitivity reactions to carbamazepine: characterization of the
specificity, phenotype, and cytokine profile of drug-specific T cell clones.
Mol Pharmacol 2003, 63(3):732–741.
20. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P,
et al: Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic
T cells. J Allergy Clin Immunol 2004, 114(5):1209–1215.
21. Park KJ, Kim JR, Joo EY, Seo DW, Hong SB, et al: Drug Interaction and
Pharmacokinetic Modeling of Oxcarbazepine in Korean Patients With
Epilepsy. Clin Neuropharmacol 2012, 35(1):40–4.
22. Zaccara G, Franciotta D, Perucca E: Idiosyncratic adverse reactions to
antiepileptic drugs. Epilepsia 2007, 48(7):1223–44.
23. Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW,
et al: Comparison and predictors of rash associated with 15 antiepileptic
drugs. Neurology 2007, 68(20):1701–9.
24. Klassen BD, Sadler RM: Induction of hypersensitivity to a previously
tolerated antiepileptic drug by a second antiepileptic drug.
Epilepsia 2001, 42(3):433–5.
doi:10.1186/1471-2377-13-75
Cite this article as: Lv et al.: The association between oxcarbazepine-
induced maculopapular eruption and HLA-B alleles in a Northern Han
Chinese population. BMC Neurology 2013 13:75.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
